Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for idiopathic multicentric Castleman disease has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
129 publications have been identified in PubMed for idiopathic multicentric Castleman disease. Research spans Case Report / Case Series (43%), Review / Meta-Analysis (18%), and Other (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 55 | 43% |
Data assembled from 4 of 12 sources · Last updated Nov 3, 2026, 5:04 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries |
23 |
18% |
Other research | 12 | 9% |
Laboratory research | 11 | 9% |
Disease patterns and progression | 11 | 9% |
Testing and diagnosis research | 8 | 6% |
Clinical study results | 8 | 6% |
New treatment approaches | 1 | 1% |
Fukui S (2026). [PMID: 41711072](https://pubmed.ncbi.nlm.nih.gov/41711072/). *Mod Rheumatol*. [Clinical Trial Publication]
Quon S (2026). [PMID: 41840344](https://pubmed.ncbi.nlm.nih.gov/41840344/). *Am J Hematol*. [Case Report / Case Series]
Pelliccia S (2026). [PMID: 41889412](https://pubmed.ncbi.nlm.nih.gov/41889412/). *Front Oncol*. [Other]
Umeda M (2026). [PMID: 41365367](https://pubmed.ncbi.nlm.nih.gov/41365367/). *Immunol Lett*. [Epidemiology / Natural History]
Ke H (2026). [PMID: 41693259](https://pubmed.ncbi.nlm.nih.gov/41693259/). *Br J Haematol*. [Case Report / Case Series]
Sastre Ortega J (2026). [PMID: 42014163](https://pubmed.ncbi.nlm.nih.gov/42014163/). *BMJ Case Rep*. [Case Report / Case Series]
Kamarádová K (2026). [PMID: 41996258](https://pubmed.ncbi.nlm.nih.gov/41996258/). *Cesk Patol*. [Review / Meta-Analysis]
Li S (2026). [PMID: 41726392](https://pubmed.ncbi.nlm.nih.gov/41726392/). *Hemasphere*. [Other]
Masuzawa N (2026). [PMID: 41975025](https://pubmed.ncbi.nlm.nih.gov/41975025/). *Clin Exp Nephrol*. [Epidemiology / Natural History]
Ueda Y (2026). [PMID: 41100060](https://pubmed.ncbi.nlm.nih.gov/41100060/). *Rheumatology (Oxford)*. [Epidemiology / Natural History]
AI-curated news mentioning idiopathic multicentric Castleman disease
Updated Oct 24, 2026
hhv8 associated multicentric castleman disease with kaposi sarcoma in an immunocompetent patient a case report and review of the literature
A recent study analyzed the morbidity burden and healthcare costs associated with idiopathic multicentric Castleman disease (iMCD). The retrospective cohort analysis provides valuable insights into the economic impact of this rare disease.
A recent study highlights that pediatric idiopathic multicentric Castleman disease often presents with severe symptoms but shows responsiveness to treatment with siltuximab. This finding underscores the potential for effective management of this rare condition in children.